

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


PATENT
Attorney Docket No.: 022205-000110US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



On December 2, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nikhilesh N. Singh, et al.

Application No.: 10/763,641

Filed: January 22, 2004

For: METHODS AND COMPOSITIONS
FOR DELIVERING 5-HT₃
ANTAGONISTS ACROSS THE ORAL
MUCOSA

Examiner: To Be Assigned

Art Unit: 1615

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with the Office's waiver, issued in the August 5, 2003 Official Gazette, copies of the cited U.S. patent publications are not enclosed. Copies of all other references are submitted herewith. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the International Search Report issued in connection with the corresponding International Patent Application No. PCT/US04/01807.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



William B. Kezer
Reg. No. 37,369

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895
WBK:jvl
60318071 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/763,641
		Filing Date	January 22, 2004
		First Named Inventor	Singh, Nikhilesh N.
		Art Unit	1615
		Examiner Name	To Be Assigned
Sheet 1	of 5	Attorney Docket Number	022205-000110US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1.	3,806,290	04-23-1974	Graff et al.	
	2.	4,151,270	04-24-1979	Ream et al.	
	3.	4,209,505	06-24-1980	Mikhail	
	4.	4,276,296	06-30-1981	Brown et al.	
	5.	4,405,647	09-20-1983	Fisher et al.	
	6.	4,438,100	03-20-1984	Balslev et al.	
	7.	4,671,953	06-09-1987	Stanley et al.	
	8.	4,816,470	03-28-1989	Dowle et al.	
	9.	4,820,506 A	04-11-1989	Kleinberg et al.	
	10.	4,863,737	09-05-1989	Stanley et al.	
	11.	4,906,455	03-06-1990	Hoerman	
	12.	4,917,674	04-17-1990	Molinoff	
	13.	4,938,963	07-03-1990	Parnell	
	14.	5,037,845	08-06-1991	Oxford	
	15.	5,047,245 A	09-10-1991	Bally et al.	
	16.	5,132,114	07-21-1992	Stanley et al.	
	17.	5,198,436 A	03-30-1993	Ellinwood, Jr. et al.	
	18.	5,288,497	02-22-1994	Stanley et al.	
	19.	5,288,498	02-22-1994	Stanley et al.	
	20.	5,376,672	12-27-1994	Pilgrim	
	21.	5,393,773	02-28-1995	Craig et al.	
	22.	5,554,639	09-10-1996	Craig et al.	
	23.	5,571,528	11-05-1996	Lee et al.	
	24.	5,607,967	03-04-1997	Friedman et al.	
	25.	5,686,094	11-11-1997	Acharya	
	26.	5,705,520	01-06-1998	Craig et al.	
	27.	5,731,338 A	03-24-1998	Acharya	
	28.	5,744,482 A	04-28-1998	Cohen et al.	
	29.	5,783,207	07-21-1998	Stanley et al.	
	30.	5,785,989	07-28-1998	Stanley et al.	
	31.	5,811,446 A	09-22-1998	Thomas	
	32.	5,824,334	10-20-1998	Stanley et al.	
	33.	5,855,908	01-05-1999	Stanley et al.	
	34.	5,863,559	01-26-1999	Phillips et al.	
	35.	5,872,145	02-16-1999	Plachetka	
	36.	5,955,098 A	09-21-1999	Dugger, III	
	37.	5,981,526 A	11-09-1999	Hargreaves	
	38.	6,020,001	02-01-2000	Phillips et al.	
	39.	6,060,499 A	05-09-2000	Plachetka	
	40.	6,077,539 A	06-20-2000	Plachetka et al.	
	41.	6,110,486 A	08-29-2000	Dugger, III	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/763,641
		Filing Date	January 22, 2004
		First Named Inventor	Singh, Nikhilesh N.
		Art Unit	1615
		Examiner Name	To Be Assigned
Sheet 2 of 5	Attorney Docket Number	022205-000110US	

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	42.	6,197,334	03-06-2001	Renda	
	43.	6,200,604 B1	03-13-2001	Pather et al.	
	44.	6,255,502	07-03-2001	Penkler et al.	
	45.	6,264,981 B1	07-24-2001	Zhang et al.	
	46.	6,344,222 B1	02-05-2002	Cherukuri et al.	
	47.	6,358,060 B2	03-19-2002	Pinney et al.	
	48.	6,368,627	04-09-2002	Phillips et al.	
	49.	6,383,471 B1	05-07-2002	Chen et al.	
	50.	6,391,282 B1	05-21-2002	Dugger, III	
	51.	6,465,003 B1	10-15-2002	Ream et al.	
	52.	6,476,042 B1	11-05-2002	Harrison	
	53.	6,479,551 B1	11-12-2002	Plachetka et al.	
	54.	6,552,024 B1	04-22-2003	Chen et al.	
	55.	6,558,692 B1	05-06-2003	Ream et al.	
	56.	6,586,458 B1	07-01-2003	Plachetka	
	57.	2002/0006440 A1	01-17-2002	Cherukuri	
	58.	2002/0018800 A1	02-14-2002	Pinney et al.	
	59.	2002/0044960 A1	04-18-2002	Cherukuri	
	60.	2002/0044962 A1	04-18-2002	Cherukuri et al.	
	61.	2002/0098264 A1	07-25-2002	Cherukuri et al.	
	62.	2002/0102304 A1	08-01-2002	Pinney et al.	
	63.	2002/0160043 A1	10-31-2002	Coleman	
	64.	2002/0187188 A1	12-12-2002	Cherukuri	
	65.	2002/0192242 A1	12-19-2002	Hsu et al.	
	66.	2002/0192243 A1	12-19-2002	Hsu et al.	
	67.	2002/0192300 A1	12-19-2002	Luo et al.	
	68.	2002/0192301 A1	12-19-2002	Luo et al.	
	69.	2002/0192302 A1	12-19-2002	Hsu et al.	
	70.	2002/0197284 A1	12-26-2002	Luo et al.	
	71.	2003/0017202 A1	01-23-2003	Bunick et al.	
	72.	2003/0018031 A1	01-23-2003	Guterman et al.	
	73.	2003/0035839 A1	02-20-2003	Hirsh et al.	
	74.	2003/0040537 A1	02-27-2003	Plachetka et al.	
	75.	2003/0049208 A1	03-13-2003	Ream et al.	
	76.	2003/0050620 A1	03-13-2003	Odidi et al.	
	77.	2003/0064097 A1	04-03-2003	Patel et al.	
	78.	2003/0068356 A1	04/10/2003	Pather et al.	
	79.	2003/0077227 A1	04-24-2003	Dugger III	
	80.	2003/0091629 A1	05-15-2003	Pather et al.	
	81.	2003/0104041 A1	06-05-2003	Hsu et al.	
	82.	2003/0124184 A1	07-03-2003	Mezaache et al.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60318071 v1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/763,641	
			Filing Date	January 22, 2004	
			First Named Inventor	Singh, Nikhilesh N.	
			Art Unit	1615	
			Examiner Name	To Be Assigned	
Sheet	3	of	5	Attorney Docket Number	022205-000110US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	83.	2003/0165566 A1	09-04-2003	O'Toole et al.	
	84.	2003/0185884 A1	10-02-2003	Singh et al.	
	85.	2003/0203022 A1	10-30-2003	Mizumoto et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	86.	EP	0 433 043	A1	06-19-1991	Peirce Management		<input type="checkbox"/>
	87.	EP	1 260 216	A1	11-27-2002	Peirce Management		<input type="checkbox"/>
	88.	GB	2 290 963	A	01-17-1996	Prendergast et al.		<input type="checkbox"/>
	89.	WO	92/14708	A1	09-03-1992	Glaxo Group		<input type="checkbox"/>
	90.	WO	94/01091	A1	01-20-1994	TNO		<input type="checkbox"/>
	91.	WO	98/02186	A1	01-22-1998	Farmarc Nederland		<input type="checkbox"/>
	92.	WO	98/42344	A1	10-01-1998	Green		<input type="checkbox"/>
	93.	WO	00/06161	A1	02-20-2000	Jackson		<input type="checkbox"/>
	94.	WO	00/13662	A2	03-16-2000	Henningfield		<input type="checkbox"/>
	95.	WO	00/66115	A1	11-09-2000	Glaxo Group		<input type="checkbox"/>
	96.	WO	00/67799	A1	11-16-2000	Dettmar		<input type="checkbox"/>
	97.	WO	01/39836	A1	06-07-2001	Natco Pharma Ltd.		<input type="checkbox"/>
	98.	WO	01/41749	A2	06-14-2001	Glaxo Grp. Ltd.		<input type="checkbox"/>
	99.	WO	01/89476	A1	11-29-2001	NPD LLC		<input type="checkbox"/>
	100.	WO	02/13781	A1	02-21-2002	Andersen		<input type="checkbox"/>
	101.	WO	02/102357	A1	12-27-2002	Olsson Roland		<input type="checkbox"/>
	102.	WO	03/039518	A1	05-15-2003	Adusumilli Prasad		<input type="checkbox"/>
	103.	WO	03/084515	A1	10-16-2003	Transoral Pharmaceuticals		<input type="checkbox"/>
	104.	WO	03/086343	A2	10-23-2003	Cadila Healthcare		<input type="checkbox"/>
	105.	WO	03/092591	A2	11-13-2003	NPD LLC		<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60318071.v1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,641
				Filing Date	January 22, 2004
				First Named Inventor	Singh, Nikhilesh N.
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	4	of	5	Attorney Docket Number	022205-000110US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	106.	AUNGST, B.J., "Site-dependence and structure-effect relationships for alkylglycosides as transmucosal absorption promoters for insulin" Int. J. Pharm. 105:219-225 (1994).		
	107.	AUNGST, B.J. and ROGERS, N.J., "Site dependence of absorption-promoting actions of laurith-9, Na salicylate, Na ₂ EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery" Pharm. Res. 5(5):305-308 (1988).		
	108.	AUNGST, B.J. and ROGERS, N.J., "Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery" Int. J. Pharm. 53:227-235 (1989).		
	109.	AUNGST, B.J. et al., "Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter" J. Pharmacol. Exp. Ther. 244(1):23-27 (1988).		
	110.	COUTEL-EGROS, A. et al., "Combined effects of pH, cosolvent and penetration enhancers on the in vitro buccal absorption of propranolol through excised hamster cheek pouch" Int. H. Pharm. 84:117-128 (1992).		
	111.	GANDHI, R. and ROBINSON, J., "Mechanisms of penetration enhancement for transbuccal delivery of salicylic acid" Int. J. Pharm. 85:129-140 (1992).		
	112.	GARETH, W., et al., "F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT _{1B/1D} receptors in models relevant to migraine" J. Pharm. Exp. Ther. 290(1):83-95 (1999), Abstract only.		
	113.	GREEN, J.A. et al., "The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting" Cancer Chemother. Pharmacol. 24:137-139 (1989).		
	114.	HOOGSTRAATE, A.J. et al., "Buccal delivery of fluorescein isothiocyanate-dextran 4400 and the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs" J. Control. Rel. 41:77-84 (1996).		
	115.	KANSEY, M. et al., "Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes" J. Med. Chem. 41(7):1007-1010 (1998).		
	116.	KUROSAKI, Y. et al., "Effects of surfactants on the absorption of salicylic acid from hamster cheek pouch as a model of keratinized oral mucosa" Int. J. Pharm. 47:13-19 (1988).		
	117.	KUROSAKI, Y. et al., "Enhancing effect of 1-dodecylazacycloheptan-2-one (azon) on the absorption of salicylic acid from keratinized oral mucosa and the duration of enhancement in vivo" Int. J. Pharm. 51:47-54 (1989).		
	118.	LIEBERMAN, H.A. et al., (eds.), <u>Pharmaceuticals Dosage Forms: Tablets</u> Second Ed., Marcel Dekker, Inc., New York, NY, Vol. 1, pp.vii-x, Table of Contents only (1989).		
	119.	MANGANARO, A.M. and WERTZ, P.W., "The effects of permeabilizers on the in vitro penetration of propranolol through porcine buccal epithelium" Mil. Med. 161(11):669-672 (1996).		
	120.	NAKANE, S. et al., "Oramucosal delivery of LHRH: pharmacokinetic studies of controlled and enhanced transmucosal permeation" Pharmac. Devel. Techn. 1(3):251-259 (1996).		
	121.	OH, C.K. and RITSCHER, W.A., "Biopharmaceutic aspects of buccal absorption of insulin" Meth. Find. Exp. Clin. Pharmacol. 12(3):205-212 (1990).		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/763,641
				Filing Date	January 22, 2004
				First Named Inventor	Singh, Nikhilesh N.
				Art Unit	1615
				Examiner Name	To Be Assigned
Sheet	5	of	5	Attorney Docket Number	022205-000110US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	122.	PATHER, S. et al., "Enhanced buccal delivery of fentanyl using the oravescent drug delivery system" Drug Delivery Technology 1(1):8 pages (2001).	
	123.	RATHBONE, M. et al., "The oral cavity as a site for systemic drug delivery" Adv. Drug Del. Rev. 13:1-22 (1994).	
	124.	SHOJAEI, A. et al., "Buccal Mucosa as a route for systemic drug delivery: a review" J. Pharm. Pharmaceut. Sci. 1(1):15-30 (1998).	
	125.	SIEGAL, I.A. and GORDON, H.P., "Effects of surfactants on the permeability of canine oral mucosa in vitro" Tox. Lett. 26:153-157 (1985).	
	126.	SIEGAL, I.A. and GORDON, H.P., "Surfactant-induced increases of permeability of rat oral mucosa to non-electrolytes in vivo" Arch. Oral Biol. 30(1):43-47 (1985).	
	127.	STEWART, A. et al., "The effect of enhancers on the buccal absorption of hybrid (BDBB) α -interferon" Int. J. Pharm. 104:145-149 (1994).	
	128.	WOLANY, G.J.M. et al., "Buccal absorption of sandostatin (octreotide) in conscious beagle dogs" Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 17:224-225 (1990).	
	129.	ZHANG, J. et al., "An in vivo dog model for studying recovery kinetics of the buccal mucosa permeation barrier after exposure to permeation enhancers: apparent evidence of effective enhancement without tissue damage" Int. J. Pharm. 101:15-22 (1994).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

IFW

DEC 06 2004

PTO/SB/21 (09-04)

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

12

Application Number

10/763,641

Filing Date

January 22, 2004

First Named Inventor

Singh, Nikhilesh N.

Art Unit

1615

Examiner Name

To Be Assigned

Attorney Docket Number

022205-000110US

ENCLOSURES (Check all that apply)

Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a
Provisional ApplicationPower of Attorney, Revocation
Change of Correspondence Address

Terminal Disclaimer



Request for Refund



CD, Number of CD(s) _____



Landscape Table on CD



After Allowance Communication to TC

Appeal Communication to Board
of Appeals and InterferencesAppeal Communication to TC
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify
below):Copy of International Search Report (4
pages);
References (44);
Return PostcardCertified Copy of Priority
Document(s)Reply to Missing Parts/ Incomplete
ApplicationReply to Missing Parts
under 37 CFR 1.52 or 1.53


Remarks

The Commissioner is authorized to charge any additional fees to Deposit
Account 20-1430.**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name

Townsend and Townsend and Crew LLP

Signature



Printed name

William B. Kezer

Date

December 2, 2004


Reg. No.

37,369

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature



Typed or printed name

Jose Luna

Date

December 2, 2004